Compare NEO & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEO | EVO |
|---|---|---|
| Founded | 2001 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 934.1M |
| IPO Year | 2008 | N/A |
| Metric | NEO | EVO |
|---|---|---|
| Price | $8.77 | $2.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $13.38 | $7.00 |
| AVG Volume (30 Days) | ★ 2.1M | 91.4K |
| Earning Date | 04-28-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.63 | $1.37 |
| Revenue Next Year | $9.73 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $2.31 |
| 52 Week High | $13.74 | $4.80 |
| Indicator | NEO | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 46.32 |
| Support Level | $8.68 | $2.63 |
| Resistance Level | $8.84 | $3.78 |
| Average True Range (ATR) | 0.43 | 0.09 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 41.77 | 33.38 |
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.